atezolizumab (Tecentriq)

following a full submission assessed under the end of life and orphan medicine process:

atezolizumab (Tecentriq®) is accepted for use within NHSScotland.

Indication under review: Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have programmed death-ligand 1 [PD-L1] expression ≥1% and who have not received prior chemotherapy for metastatic disease.

In a randomised, double-blind, phase III study, the addition of atezolizumab to nab-paclitaxel significantly improved progression-free survival and numerically improved overall survival in patients with locally advanced or metastatic triple-negative breast cancer with PD-L1 expression ≥1% who had not received prior chemotherapy for metastatic disease.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.